GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Doesn't that ignore the fact that GTCB's version should be much cheaper, even if the analogue's are both better and gain approval?<

There’s no question that GTC expects to compete successfully on price against any and all comers in the market for FVIIa and FVIIa analogues. What I was trying to emphasize in the previous posts is that the FVIIa analogues are not a lock to obtain regulatory approval because they are not FVIIa per se and they may have newfound safety issues. Regards, Dew